MarginsXMarginsX
Home › Markets › Health Care › QUIT

Achieve Life Sciences Inc. Common Shares (QUIT)

QUIT trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.06
-4.11% on the day
Market cap
$666.8M
Small cap
Revenue · 2019
$0
No prior year to compare
Net income · 2019
-$16.4M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2019-12-31, https://www.sec.gov/Archives/edgar/data/949858/000156459020010642/0001564590-20-010642-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2019-12-31.

Profile

FieldValue
TickerQUIT on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000949858
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inDE

Financials · 2019

LineValue
Revenue$0
Net income-$16.4M
Operating incomeNot in SEC XBRL data
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$16.7M
Total assets$21.1M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
16.3 months
$59.7M cash at September 30, 2026
Share count, 1 year
+106.7%
2025-11-06 to 2026-11-10 · +419.9% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$175K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$59.7M cash; operating cash flow -$11.0M a quarter.Report 2026-09-30
Shares outstanding110,034,457 (2026-11-10); 53,233,988 a year earlier; 21,165,760 three years earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-08-14
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Vancouver, CanadaPCAOB Form AP 2026-04-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $175K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$12.1M-$8.4M$59.7M$13.0MNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$74.8M-$10.8M$48.0M$14.9MNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$10.2M-$6.9M$28.1M$14.9MNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$14.7M-$18.0M$20.9M$14.9MNeeds four quarters10-K 2026-03-24
Q3 2025
2025-09-30
Not filed-$14.4M-$11.3M$31.9M$9.9MNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$12.7M-$9.1M$51.9M$9.9MNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$12.8M-$11.1M$13.0M$9.9MNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$12.4M-$9.2M$12.8M$9.8MNeeds four quarters10-K 2026-03-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-14
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-06-08

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.0%
1 month-9.7%
3 months-12.8%
Year to date+27.2%
1 year+38.0%
From 52-week high-25.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
QDELQuidelOrtho Corporation$10.21-4.93%$700.5M
NNNNAnbio Biotechnology$3.88+1.57%$558.3M
MYGNMyriad Genetics Inc.$5.57-1.59%$534.3M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M
NTLAIntellia Therapeutics Inc.$9.86+1.65%$1.4B
CLDXCelldex Therapeutics Inc.$28.59-0.83%$2.2B
NEOGNeogen Corporation$10.88-3.12%$2.4B
ICCCImmuCell Corporation$11.42+6.23%$103.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier